Physician

Biren P Saraiya, M.D.

According to 2025 Medicare claims, Biren Saraiya, M.D. (NPI: 1518173665) practices medical oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (NPI: 1518904929; TIN: 223371727) and primary practice location at 08901-1992. Saraiya is affiliated with the Summit Health ACO (ACO ID: A5049) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Saraiya's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 173 traditional Medicare patients, billed 683 HCPCS/CPT codes, and received $47,883 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 675 prescription claims across 95 beneficiaries totaling $1,020,331 in drug costs, led by Xtandi (Enzalutamide). 2016 DME data shows 36 claims. Open Payments data shows 54 records totaling $825,169. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $309,412 to $47,883. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $430,127 to $1,020,331. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	425	29,754	$309,412
2016	328	44,988	$487,681
2017	372	66,159	$622,713
2018	313	15,654	$215,465
2019	219	959	$121,472
2020	197	681	$74,177
2021	222	659	$69,584
2022	169	522	$51,499
2023	181	486	$41,380
2024	173	683	$47,883

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	104	400	$430,127
2016	87	377	$244,115
2017	113	528	$220,804
2018	102	388	$709,289
2019	103	590	$1,392,117
2020	114	750	$1,643,341
2021	113	660	$1,343,118
2022	98	521	$678,678
2023	91	510	$742,116
2024	95	675	$1,020,331

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$976
2016	N/R	36	$1,051
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	37	37	$150
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	65	132	$118
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	15	17	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	112	233	$75
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	101	202	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	36	1,080	$459,085
Abiraterone Acetate	Abiraterone Acetate	131	4,048	$58,901
Orgovyx	Relugolix	22	660	$56,022
Bicalutamide	Bicalutamide	27	1,230	$616
Dexamethasone	Dexamethasone	42	1,819	$542

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$30	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	52	$825,139	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Biren P. Saraiya, M.D.?

Tedicare shows public-source Medicare data for Biren P. Saraiya, M.D. (NPI 1518173665), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Biren P. Saraiya, M.D. have ACO affiliation data?

Biren P. Saraiya, M.D. is shown with ACO affiliation data for Summit Health ACO (MSSP, ACO ID A5049) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Biren P. Saraiya, M.D.?

Biren P. Saraiya, M.D. is linked to RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (billing NPI 1518904929) in the available physician profile data.

Does Biren P. Saraiya, M.D. have Open Payments data?

Biren P. Saraiya, M.D. has 54 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.